Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

<i>Background and Objectives:</i> ROS1 rearrangement is a rare but targetable alteration in non-small-cell lung cancer (NSCLC), occurring in 1–2% of cases. Crizotinib, a tyrosine kinase inhibitor, has demonstrated efficacy in clinical trials, but real-world data remain limited. This stud...

Full description

Saved in:
Bibliographic Details
Main Authors: Alper Topal, Goncagul Akdag, Sedat Yildirim, Oguzcan Kinikoglu, Deniz Isik, Gizem Yildirim, Salih Tunbekici, Fatih Kus, Aydın Acarbay, Murad Guliyev, Nargiz Majidova, Yasin Kutlu, Mustafa Erman, Hatice Odabas, Nedim Turan, Nuri Karadurmus
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Medicina
Subjects:
ROS1
lung cancer
crizotinib
Online Access:https://www.mdpi.com/1648-9144/61/3/490
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items